Scott K. Pruitt

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 3K citations · Full text

Life Sciences, Immunology, Oncology +17

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Hyun Cheol Chung, Willeke Ros, Jean‐Pierre Delord et al. · Journal of Clinical Oncology · 2019 · 1.1K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.

Zhen Su, Jens Dannull, Axel Heiser et al. · PubMed · 2003 · 368 citations · Full text

Medicine, Immunology, Oncology +17

THE EFFECT OF SOLUBLE COMPLEMENT RECEPTOR TYPE 1 ON HYPERACUTE REJECTION OF PORCINE XENOGRAFTS

Scott K. Pruitt, Allan D. Kirk, R. Randal Bollinger et al. · Transplantation · 1994 · 263 citations

Life Sciences, Immunology, Surgery +17

Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

Hyun Cheol Chung, José A. López-Martín, Stephen Chuan-Hao Kao et al. · Journal of Clinical Oncology · 2018 · 208 citations

Pharmacy, Oncology, Pharmacotherapy +17